Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2011
Business Overview: pSivida develops sustained-release drug delivery products for chronic eye diseases using its Durasert and BioSilicon technologies. The company has no internal sales force and relies on strategic partners for commercialization.
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 |
|---|---|---|
| Total Revenues | $4.97 million | $23.05 million |
| Net (Loss) Income | $(8.63) million | $8.75 million |
| Operating Expenses | $14.97 million | $13.96 million |
| Cash and Cash Equivalents | $12.91 million | $15.51 million |
| Marketable Securities | $11.22 million | $2.05 million |
| Total Liquidity (Cash + Securities) | $24.13 million | $17.56 million |
| Intangible Assets (Net) | $21.56 million | $23.88 million |
| Accumulated Deficit | $(226.92) million | $(218.30) million |
Note: The filing does not provide specific debt figures as the company has no long-term debt obligations listed on the balance sheet.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 78% ($18.1 million) compared to fiscal 2010. This was primarily due to a significant drop in collaborative research revenue from Alimera Sciences, Inc. ($22.3 million in 2010 vs. $0.19 million in 2011), as the 2010 figure included a one-time $15 million conditional note payment.
- Profitability Shift: The company swung from a net income of $8.75 million in 2010 to a net loss of $8.63 million in 2011. The 2010 income was driven by the Alimera note payment and a gain on the change in fair value of derivatives.
- Derivative Liability Impact: The change in fair value of derivative liabilities (A$-denominated warrants) resulted in $1.14 million of income in 2011, compared to a $0.34 million expense in 2010, largely due to the expiration of approximately 3.7 million warrants.
- Operating Expenses: General and administrative expenses increased by 16% ($1.1 million) due to higher stock-based compensation and professional fees. Research and development expenses remained relatively flat, decreasing slightly by 2%.
Guidance, Outlook, and Risks
Product Pipeline and Regulatory Status
- ILUVIEN (DME): The lead product candidate, licensed to Alimera, is under FDA review for Diabetic Macular Edema (DME). Alimera resubmitted the New Drug Application (NDA) in May 2011 following a Complete Response Letter. A PDUFA decision date is expected in November 2011. Approval could trigger a $25 million milestone payment to pSivida.
- Latanoprost Product (Glaucoma): In June 2011, pSivida amended its agreement with Pfizer to focus solely on a bioerodible latanoprost implant. Pfizer paid a $2.3 million upfront fee. pSivida recognized $3.3 million in revenue immediately due to accounting changes (ASU 2009-13) regarding the modification of the agreement.
- Posterior Uveitis: An investigator-sponsored Phase I/II study opened in September 2011 for an injectable insert delivering fluocinolone acetonide.
Liquidity and Capital Resources
Management believes current cash and marketable securities ($24.1 million) are sufficient to fund operations into at least calendar year 2013. Future funding beyond this period is heavily dependent on the FDA approval and commercialization of ILUVIEN.
Key Risks
- Regulatory Approval: Failure of the FDA to approve ILUVIEN would materially harm the business and cash position.
- Intangible Asset Impairment: The company holds $21.6 million in intangible assets (Durasert and BioSilicon). If the Latanoprost product does not advance to advanced clinical trials by late fiscal 2012, the BioSilicon asset could be fully impaired.
- Collaboration Dependence: The company relies entirely on partners (Alimera, Pfizer, Bausch & Lomb) for development and commercialization. Partners may terminate agreements or fail to exercise options.
Investor Verification Checklist
- ILUVIEN FDA Decision: Verify the outcome of the FDA review expected in November 2011, as this dictates the receipt of the $25 million milestone payment.
- Pfizer Option Exercise: Monitor whether Pfizer exercises its option to license the Latanoprost Product upon completion of Phase II trials, which would trigger a $20 million payment.
- Intangible Asset Valuation: Review future disclosures regarding the recoverability of the $14.7 million BioSilicon intangible asset, particularly if clinical progress stalls.
- Derivative Liability Exposure: Confirm the expiration of remaining A$-denominated warrants (July 2012) to assess future volatility in operating results.
- Cash Burn Rate: Track quarterly cash usage to ensure the runway extends through 2013 without additional dilutive financing.